Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hanabusa

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2011
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trialA Shirahata, K Fukutake, J Mimaya, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 20, 2012
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd reportA Shirahata, K Fukutake, J Mimaya, et al.
International Journal of Hematology|August 16, 2001
Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitorsA Shirahata, T Kamiya, J Takamatsu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2015
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia AB Nolan, J Mahlangu, D Perry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 7, 2013
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamicsA Shirahata, K Fukutake, J Takamatsu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 3, 2016
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitorsY Shinkoda, A Shirahata, K Fukutake, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsA D Shapiro, M V Ragni, R Kulkarni, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 4, 2011
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trialA Shirahata, K Fukutake, J Mimaya, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 20, 2012
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd reportA Shirahata, K Fukutake, J Mimaya, et al.
International Journal of Hematology|August 16, 2001
Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitorsA Shirahata, T Kamiya, J Takamatsu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 29, 2015
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia AB Nolan, J Mahlangu, D Perry, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 7, 2013
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamicsA Shirahata, K Fukutake, J Takamatsu, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 3, 2016
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitorsY Shinkoda, A Shirahata, K Fukutake, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2014
Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levelsA D Shapiro, M V Ragni, R Kulkarni, et al.
Pageof 2